GLP1R and polycystic ovary syndrome: A consolidated clinical signal from clinical trials, meta-analyses, and narrative reviews indicates that GLP-1 receptor agonists consistently enhance metabolic dysfunction, menstrual regularity, ovulation, and, in many instances, natural conception rates in overweight or obese individuals with PCOS.